<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB2512</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB2512 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB2512</pre></b></center><p> </p>Introduced 2/4/2025, by Rep. Jed Davis<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>New Act</code></td><td class="synopsis"></td></tr><tr><td class="synopsis"><code>30 ILCS 105/5.1030 new</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Creates the Accountability in Psychotropic Drug Prescriptions for </code><code>Children Under Medicaid Act. Requires medical care providers prescribing </code><code>psychotropic drugs to children under the State's Medicaid program to </code><code>provide FDA Medication Guides to parents or legal guardians before issuing </code><code>a prescription. Provides that the Medication Guides must be printed and </code><code>reviewed with the parent or legal guardian, explaining (1) FDA-identified </code><code>risks of the medication, including pediatric-specific warnings and (2) </code><code>signs of potential side effects and adverse drug reactions detailed in the </code><code>Medication Guide. Provides that written informed consent must be obtained </code><code>from the parent or legal guardian before prescribing a psychotropic drug. </code><code>Requires the Department of Healthcare and Family Services to, within 12 </code><code>months after the effective date of the Act, develop and maintain a secure </code><code>online reporting system for adverse drug reactions related to psychotropic </code><code>drugs prescribed to children and adolescents. Contains provisions on </code><code>adverse drug reaction reporting requirements; legislative oversight and </code><code>reviews of adverse drug reaction reports related to psychotropic drugs; </code><code>penalties for medical care providers who fail to comply with medication </code><code>guide distribution; transparency and accountability reporting requirements </code><code>for the Department of Healthcare and Family Services; and other matters. </code><code>Amends the State Finance Act. Creates the Medicaid Oversight and Safety </code><code>Measures Fund.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning health care.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 1. </code><code>Short title. </code><code>This Act may be cited as the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Accountability in Psychotropic Drug Prescriptions for Children </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Under Medicaid Act.</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>Legislative findings. </code><code>The General Assembly </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>finds the following:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) In 2023, Illinois' Medicaid program statistics </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>showed 96,841 children and adolescents aged 0-17 being </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>prescribed psychotropic drugs, including 7,227 children </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>aged 0-5.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) The administration of nearly every psychotropic </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>drug to children aged 0-5 is off-label, meaning the drugs </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>are being prescribed for age groups not approved by the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>U.S. Food and Drug Administration (FDA).</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Psychotropic drugs, including stimulants, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>antidepressants, antipsychotics, and other behavioral </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>drugs, are being prescribed to children using Medicaid </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>funding and are documented by the FDA to include severe </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>side effects, including, but not limited to, addiction, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>suicidal ideation, aggression, hallucinations, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>cardiovascular events, stunted growth, and developmental </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>concerns.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Parents and caregivers are frequently not informed </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>of the FDA-documented risks associated with the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>psychotropics being prescribed, including the pediatric </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>risks.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Section 208.20 of Title 21 of the United States </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>Code of Federal Regulations (CFR) establishes the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>requirement for FDA Medication Guides to provide easily </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>understandable information about the risks and side </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>effects of prescription drugs for the average consumer, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>including parents and caregivers. According to federal </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>regulations, Medication Guides must:</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Detail "the particular serious and significant </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <code>public health concern that has created the need for </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <code>the Medication Guide". </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Note any known "pediatric risks".</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) Include the risk of "patients developing </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <code>dependence on the drug product".</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(D) Use a font size no smaller than 10-point.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(E) Be written in "nontechnical, understandable </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <code>language". </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(F) "Not be promotional in tone or content". </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) To effectively monitor the effects of psychotropic </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>drugs prescribed to children and adolescents, particularly </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>the FDA-cited "pediatric effects", parents and caregivers </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>must be given a hard copy of the FDA Medication Guide for </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>the psychotropic drug being prescribed.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Medicaid is a state and federally funded program </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>that provides essential healthcare services to vulnerable </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>populations, including children and adolescents. It should </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>be required to distribute the FDA Medication Guides to </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>ensure recipients and their guardians are fully informed </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>of the risks and potential adverse effects of psychotropic </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>medications, thereby supporting informed consent and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>promoting patient safety.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) A reliable system for parents and caregivers to </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>report adverse drug reactions to psychotropic drugs is </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>essential to help Medicaid agencies and legislators </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>monitor and assess the frequency, severity, and impact of </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>such reactions within the public sector.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) The absence of an accessible, Medicaid-funded </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>reporting mechanism for drug side effects limits the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>ability to identify and address these risks effectively, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>compromising the safety of children and adolescents.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Medicaid is the primary payer for psychotropic </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>medications prescribed to children and adolescents in the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>public sector, including for off-label use in children as </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>young as 0-5 years, making it directly responsible for </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>ensuring the safety and monitoring of these prescriptions.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Adverse drug reactions (ADRs) to psychotropic </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>medications can have significant physical, psychological, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>and developmental impacts on children, requiring timely </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>identification and response to mitigate harm.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) The establishment of an online ADR reporting </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>system would enable the State's Medicaid program to </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>fulfill its duty of care by providing a mechanism to </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>collect critical safety data, support evidence-based </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>decision-making, and comply with its responsibility to </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>protect public health.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Funding this reporting system aligns with the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>State's Medicaid program's obligations under federal law </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>to monitor and improve the quality of care provided to its </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>beneficiaries, especially vulnerable pediatric </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>populations, and would facilitate oversight and </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>accountability for the use of public funds in prescribing </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>psychotropic medications.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) The provisions of this Act are established to </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>address these findings and enhance oversight, informed </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>consent, and accountability in psychotropic drug </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>prescriptions for children under the State's Medicaid </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>program.</code><br> </td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 10. </code><code>Definitions. </code><code>As used in this Act:</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Adverse drug reaction" or "ADR" means any unintended </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>harmful reaction to a psychotropic drug.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Department" means the Department of Healthcare and Family </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Services.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"FDA Medication Guides" means handouts accompanying </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>certain prescription medications with significant safety </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>concerns, approved by the U.S. Food and Drug Administration </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>(FDA), to inform patients and caregivers about risks, side </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>effects, and proper usage.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Medical care providers" means any licensed health </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>professionals authorized to prescribe medication under the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>State's Medicaid program.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Online Reporting System" means a web-based platform </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>through which Medicaid beneficiaries or their guardians can </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>report ADRs related to psychotropic drugs.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Psychotropic drugs" means medications that affect the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>mind, emotions, or behavior, including, but not limited to, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>stimulants, antidepressants, antipsychotics, and other </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>behavioral drugs, authorized or funded under the State's </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Medicaid program.</code><br> </td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 15. </code><code>Informed consent requirements. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) Distribution of FDA Medication Guides:</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Medical care providers prescribing psychotropic </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>drugs to children under the State's Medicaid program must </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>provide FDA Medication Guides to parents or legal </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>guardians before issuing a prescription.</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) The Medication Guides must be printed and reviewed </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>with the parent or legal guardian, explaining:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) FDA-identified risks of the medication, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <code>including pediatric-specific warnings.</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Signs of potential side effects and adverse </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <code>drug reactions detailed in the Medication Guide.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Written and signed informed consent. Before </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>prescribing a psychotropic drug, written informed consent must </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>be obtained from the parent or legal guardian. The consent </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>must:</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Be signed by the parent or legal guardian, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>confirming that they:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Have received and reviewed the FDA Medication </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <code>Guide.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Understand the associated risks and side </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <code>effects.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Be kept on file by the medical care provider, with </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>a copy provided to the parent or legal guardian.</code><br> </td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 20. </code><code>Medicaid establishment of an Adverse Drug </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Reaction (ADR) Online Reporting System. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) Adverse drug reaction online reporting system. The </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>Department of Healthcare and Family Services shall, within 12 </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>months after the effective date of this Act, develop and </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>maintain a secure online reporting system for adverse drug </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>reactions related to psychotropic drugs prescribed to children </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>and adolescents. The system shall include the below free-text </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>fields and drop-down menus for categorizing the type of drug, </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>the nature of the adverse reaction, and the severity level. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>These features shall streamline the reporting process by </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>simplifying user input, ensuring faster processing, and </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>reducing errors for a secure online system, which will allow </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>the Department of Healthcare and Family Services to provide </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>legislators with summaries of the adverse reactions being </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>reported.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Name of Patient (free-text field)</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Age of Patient (drop-down menu)</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Class of Psychotropic Drug (drop-down menu)</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(optional to skip if the reporter doesn't know the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>category)</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Antidepressants.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Antipsychotics.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) Mood Stabilizers.</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(D) Stimulants.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(E) Anti-anxiety drugs and Sedatives.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(F) Hypnotics.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Name of Drug (free-text field)</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Adverse Reaction Category (drop-down menu)</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Physical Reaction:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(i) Gastrointestinal issues (nausea, vomiting, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >            <code>diarrhea, constipation).</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(ii) Neurological symptoms (dizziness, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >            <code>headaches, seizures, tremors).</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iii) Cardiovascular symptoms (increased heart </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >            <code>rate, blood pressure changes).</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iv) Endocrine/metabolic effects (weight </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >            <code>changes, hormonal imbalances).</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(v) Allergic reactions (rash, hives, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >            <code>anaphylaxis).</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Psychological Reaction:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(i) Mood changes (irritability, depression, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >            <code>euphoria).</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(ii) Anxiety or panic attacks.</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iii) Hallucinations or delusions.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iv) Agitation or restlessness.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(v) Suicidal thoughts or behaviors.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) Behavioral Reaction:</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(i) Sleep disturbances (insomnia, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >            <code>hypersomnia).</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(ii) Increased aggression or hostility.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iii) Manic behaviors.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(iv) Cognitive impairments (memory loss, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >            <code>confusion).</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(v) Self-harm.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>    </code><code>(vi) Disassociation.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(D) Other (free-text field)</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Severity level (drop-down menu)</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Mild.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Moderate.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) Severe.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Name of Person Reporting (free-text field)</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Relation of Person Reporting (drop-down menu)</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(required)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) Parent.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) Foster Parent.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) Relative.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(D) Legal Guardian.</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(E) Case Worker.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(F) Social Worker.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(G) Direct Care Staff.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(H) Other (free-text field).</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Email Address of Person Reporting (free-text </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>field)</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(optional, to facilitate any needed follow-up)</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Phone Number of Person Reporting (free-text </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>field)</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(optional, to facilitate any needed follow-up)</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Adverse drug reaction reporting requirements. The </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Department shall compile and submit quarterly reports </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>summarizing ADR data related to psychotropic drugs </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>administered to children and adolescents to the legislative </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>committees overseeing Medicaid funding. These reports shall </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>include:</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) The number of ADRs reported broken down by age </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>group.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) The severity level of ADRs reported.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) A breakdown of ADRs by Adverse Reaction Category </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>and severity of reactions detailing the number of </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>incidents for each category of reaction and severity.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Legislative oversight. Legislative committees shall </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>review ADR reports related to psychotropic drugs during </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>Medicaid budget hearings and program reviews and may recommend </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>actions to improve medication safety.</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Implementation. The Department shall allocate funds to </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>establish and maintain the ADR online reporting system </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>specifically for psychotropic drugs and may seek additional </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>funding as needed.</code><br> </td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 25. </code><code>Penalties for medical care provider </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>noncompliance with medication guide distribution. </code><code>Suspension </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>of Medicaid reimbursement. Medical care providers failing to </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>comply with the signed informed consent form on the Medication </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Guide may face penalties, including suspension of Medicaid </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>reimbursements.</code><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 30. </code><code>Penalty for Department noncompliance. </code><code>If the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Department fails to submit the required quarterly ADR reports </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>to the appropriate legislative committees within the specified </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>timeframe, the following penalties shall apply:</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Monetary penalty. The Department shall incur a </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>monetary fine for each quarter of noncompliance, with the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>fine amount increasing for subsequent violations. The fine </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>shall be deposited into the Medicaid Oversight and Safety </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>Measures Fund, a special fund created in the State </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>treasury for the sole purpose of improving Medicaid </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>oversight and safety measures.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Reduction in Medicaid funding. The State's </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>Medicaid program shall face a reduction in its funding </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>allocation for the following fiscal quarter until full </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>compliance is demonstrated, including the timely </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>submission of all required ADR reports.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Oversight review. The Governor or relevant State </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>oversight body shall initiate a formal review of the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>Department's operations and reporting procedures, which </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>may result in further corrective actions, including the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>appointment of an external auditor to ensure the accurate </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>and timely reporting of ADR data.</code><br> </td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 35. </code><code>Transparency and accountability reports. </code><code>The </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Department must submit annual reports to the General Assembly </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>summarizing implementation efforts, compliance statistics, and </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>the impact of this Act, including fiscal analysis and health </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>outcomes.</code><br> </td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2512</td><td class="xsl" align="center">- 12 -</td><td class="xsl" align="right">LRB104 10052 KTG 20123 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 45. </code><code>The State Finance Act is amended by adding </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>Section 5.1030 as follows:</code><br> </td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(30 ILCS 105/5.1030 new)</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 5.1030. </code></u><u><code>The Medicaid Oversight and Safety Measures </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><u><code>Fund.</code></u></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
